Capecitabine metronomic chemotherapy for maintenance treatment of metastatic colorectal cancer after reaching NED (no evidence of disease): a prospective, single center, randomized, controlled clinical study

ABSTRACT: Interventions: experimental group:Capecitabine 500mg po bid;control group:watch and wait Primary outcome(s): progression-free survival, PFS Study Design: Parallel

DISEASE(S): Colorectal Cancer

PROVIDER: 2707251 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR